Skip to main content
Erschienen in: Current Treatment Options in Oncology 1/2020

01.01.2020 | Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Locally Advanced Rectal Cancer: Treatment Approach in Elderly Patients

verfasst von: Francesca De Felice, PhD, Daniele Crocetti, PhD, Veronica Maiuri, MD, Martina Parisi, MD, Francesco Marampon, PhD, Luciano Izzo, FP, Giorgio De Toma, FP, Daniela Musio, MD, Vincenzo Tombolini, FP

Erschienen in: Current Treatment Options in Oncology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Independently of age, evidence-based guidelines recommend a multidisciplinary treatment approach in patients with locally advanced rectal cancer (LARC). But actually, elderly patients are grossly underrepresented in clinical trials, accounting < 10% of enrolled cases. Therefore, LARC management in elderly patients remains a crucial issue in daily practice, especially due to their frailty. Multiple clinical factors, including general health status, cognitive status, co-morbidity, disability, and life expectancy should be considered to understand the complexities of geriatric assessment and then define therapy. We use a patient-centered approach in order to tailor the optimal treatment strategy. We treat fit elderly patients as younger patients, including neoadjuvant chemoradiotherapy (CRT), surgery, and adjuvant chemotherapy. Whereas, in vulnerable and frail patients, we propose standard CRT (vulnerable patients) or radiotherapy alone (frail patients).
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, et al. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;2018. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, et al. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;2018.
2.
Zurück zum Zitat Rutten HJ, den Dulk M, Lemmens VE, van de Velde CJ, Marijnen CA. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol. 2008;9(5):494–501.CrossRef Rutten HJ, den Dulk M, Lemmens VE, van de Velde CJ, Marijnen CA. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol. 2008;9(5):494–501.CrossRef
3.
Zurück zum Zitat • National Comprehensive Cancer Network Guidelines, Rectal Cancer, Version 1.2019. www.nccn.org. Guidelines in rectal cancer patients. • National Comprehensive Cancer Network Guidelines, Rectal Cancer, Version 1.2019. www.​nccn.​org. Guidelines in rectal cancer patients.
4.
Zurück zum Zitat Hurria A, Dale W, Mooney M, Rowland JH, Ballman KV, Cohen HJ, et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014;32(24):2587–94.CrossRef Hurria A, Dale W, Mooney M, Rowland JH, Ballman KV, Cohen HJ, et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014;32(24):2587–94.CrossRef
5.
Zurück zum Zitat Papamichael D, Audisio R, Horiot JC, Glimelius B, Sastre J, Mitry E, et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol. 2009;20(1):5–16.CrossRef Papamichael D, Audisio R, Horiot JC, Glimelius B, Sastre J, Mitry E, et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol. 2009;20(1):5–16.CrossRef
6.
Zurück zum Zitat •• Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, et al. Treatment of colorectal cancer in elderly patients: international society of geriatric oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2015;26(3):463–76 Clinical guidelines in elderly patients with colorectal cancer.CrossRef •• Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, et al. Treatment of colorectal cancer in elderly patients: international society of geriatric oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2015;26(3):463–76 Clinical guidelines in elderly patients with colorectal cancer.CrossRef
7.
Zurück zum Zitat Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in elderly cancer patients: an update on SIOG recommendations. Ann Oncol. 2015;26(2):288–300.CrossRef Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in elderly cancer patients: an update on SIOG recommendations. Ann Oncol. 2015;26(2):288–300.CrossRef
8.
Zurück zum Zitat Guigoz Y, Lauque S, Vellas BJ. Identifying the elderly at risk for malnutrition. The mini nutritional assessment. Clin Geriatr Med. 2002;18(4):737–57.CrossRef Guigoz Y, Lauque S, Vellas BJ. Identifying the elderly at risk for malnutrition. The mini nutritional assessment. Clin Geriatr Med. 2002;18(4):737–57.CrossRef
9.
Zurück zum Zitat Kenis C, Decoster L, Van Puyvelde K, De Grève J, Conings G, Milisen K, et al. Performance of two geriatric screening tools in elderly patients with cancer. J Clin Oncol. 2014;32(1):19–26.CrossRef Kenis C, Decoster L, Van Puyvelde K, De Grève J, Conings G, Milisen K, et al. Performance of two geriatric screening tools in elderly patients with cancer. J Clin Oncol. 2014;32(1):19–26.CrossRef
10.
Zurück zum Zitat Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003;51(10):1451–4.CrossRef Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003;51(10):1451–4.CrossRef
11.
Zurück zum Zitat Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441–7.CrossRef Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441–7.CrossRef
12.
Zurück zum Zitat Kallogjeri D, Gaynor SM, Piccirillo ML, Jean RA, Spitznagel EL Jr, Piccirillo JF. Comparison of comorbidity collection methods. J Am Coll Surg. 2014;219(2):245–55.CrossRef Kallogjeri D, Gaynor SM, Piccirillo ML, Jean RA, Spitznagel EL Jr, Piccirillo JF. Comparison of comorbidity collection methods. J Am Coll Surg. 2014;219(2):245–55.CrossRef
13.
Zurück zum Zitat Hathout L, Maloney-Patel N, Malhotra U, Wang SJ, Chokhavatia S, Dalal I, et al. Management of locally advanced rectal cancer in the elderly: a critical review and algorithm. J Gastrointest Oncol. 2018;9(2):363–76.CrossRef Hathout L, Maloney-Patel N, Malhotra U, Wang SJ, Chokhavatia S, Dalal I, et al. Management of locally advanced rectal cancer in the elderly: a critical review and algorithm. J Gastrointest Oncol. 2018;9(2):363–76.CrossRef
14.
Zurück zum Zitat •• Montroni I, Ugolini G, Saur NM, Spinelli A, Rostoft S, Millan M, et al. Personalized management of elderly patients with rectal cancer: expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. Eur J Surg Oncol. 2018;44(11):1685–702 Clinical guidelines in elderly patients with rectal cancer.CrossRef •• Montroni I, Ugolini G, Saur NM, Spinelli A, Rostoft S, Millan M, et al. Personalized management of elderly patients with rectal cancer: expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. Eur J Surg Oncol. 2018;44(11):1685–702 Clinical guidelines in elderly patients with rectal cancer.CrossRef
15.
Zurück zum Zitat Musio D, De Felice F, Bulzonetti N, Guarnaccia R, Caiazzo R, Bangrazi C, et al. Neoadjuvant-intensified treatment for rectal cancer: time to change? World J Gastroenterol. 2013;19(20):3052–61.CrossRef Musio D, De Felice F, Bulzonetti N, Guarnaccia R, Caiazzo R, Bangrazi C, et al. Neoadjuvant-intensified treatment for rectal cancer: time to change? World J Gastroenterol. 2013;19(20):3052–61.CrossRef
16.
Zurück zum Zitat De Felice F, Musio D, Magnante AL, Bulzonetti N, Benevento I, Caiazzo R, et al. Disease control, survival, and toxicity outcome after intensified neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a single-institution experience. Clin Colorectal Cancer. 2016;15(2):e17–22.CrossRef De Felice F, Musio D, Magnante AL, Bulzonetti N, Benevento I, Caiazzo R, et al. Disease control, survival, and toxicity outcome after intensified neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a single-institution experience. Clin Colorectal Cancer. 2016;15(2):e17–22.CrossRef
17.
Zurück zum Zitat Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638–44.CrossRef Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638–44.CrossRef
18.
Zurück zum Zitat Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13:679–87.CrossRef Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13:679–87.CrossRef
19.
Zurück zum Zitat O’Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32(18):1927–34.CrossRef O’Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32(18):1927–34.CrossRef
20.
Zurück zum Zitat Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR- 01 randomized phase III trial. J Clin Oncol. 2011;29:2773–80.CrossRef Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR- 01 randomized phase III trial. J Clin Oncol. 2011;29:2773–80.CrossRef
21.
Zurück zum Zitat Jiao D, Zhang R, Gong Z, Liu F, Chen Y, Yu Q, et al. Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study. Chin J Cancer Res. 2015;27(6):588–96.PubMedPubMedCentral Jiao D, Zhang R, Gong Z, Liu F, Chen Y, Yu Q, et al. Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study. Chin J Cancer Res. 2015;27(6):588–96.PubMedPubMedCentral
22.
Zurück zum Zitat De Felice F, Benevento I, Magnante AL, Musio D, Bulzonetti N, Caiazzo R, et al. Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis: oxaliplatin in neoadjuvant treatment for rectal cancer. BMC Cancer. 2017;17(1):325.CrossRef De Felice F, Benevento I, Magnante AL, Musio D, Bulzonetti N, Caiazzo R, et al. Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis: oxaliplatin in neoadjuvant treatment for rectal cancer. BMC Cancer. 2017;17(1):325.CrossRef
23.
Zurück zum Zitat An X, Lin X, Wang FH, Goodman K, Cai PQ, Kong LH, et al. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis. Eur J Cancer. 2013;49(4):843–51.CrossRef An X, Lin X, Wang FH, Goodman K, Cai PQ, Kong LH, et al. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis. Eur J Cancer. 2013;49(4):843–51.CrossRef
24.
Zurück zum Zitat Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44.CrossRef Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44.CrossRef
25.
Zurück zum Zitat De Felice F, Izzo L, Musio D, Magnante AL, Bulzonetti N, Pugliese F, et al. Clinical predictive factors of pathologic complete response in locally advanced rectal cancer. Oncotarget. 2016;7(22):33374–80.CrossRef De Felice F, Izzo L, Musio D, Magnante AL, Bulzonetti N, Pugliese F, et al. Clinical predictive factors of pathologic complete response in locally advanced rectal cancer. Oncotarget. 2016;7(22):33374–80.CrossRef
26.
Zurück zum Zitat Tougeron D, Roullet B, Paillot B, Hamidou H, Tourani JM, Bensadoun RJ, et al. Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres. Dig Liver Dis. 2012;44(4):350–4.CrossRef Tougeron D, Roullet B, Paillot B, Hamidou H, Tourani JM, Bensadoun RJ, et al. Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres. Dig Liver Dis. 2012;44(4):350–4.CrossRef
27.
Zurück zum Zitat Ausili Cèfaro G, Genovesi D, Vinciguerra A, Augurio A, Di Tommaso M, Marchese R, et al. Effects of preoperative radiochemotherapy with capecitabine for resectable locally advanced rectal cancer in elderly patients. Tumori. 2012;98(5):622–9.CrossRef Ausili Cèfaro G, Genovesi D, Vinciguerra A, Augurio A, Di Tommaso M, Marchese R, et al. Effects of preoperative radiochemotherapy with capecitabine for resectable locally advanced rectal cancer in elderly patients. Tumori. 2012;98(5):622–9.CrossRef
28.
Zurück zum Zitat De Felice F, Musio D, Izzo L, Pugliese F, Izzo P, Bolognese A, et al. Preoperative chemoradiotherapy in elderly patients with locally advanced rectal cancer. Biomed Res Int. 2013;2013:610786.CrossRef De Felice F, Musio D, Izzo L, Pugliese F, Izzo P, Bolognese A, et al. Preoperative chemoradiotherapy in elderly patients with locally advanced rectal cancer. Biomed Res Int. 2013;2013:610786.CrossRef
29.
Zurück zum Zitat Margalit DN, Mamon HJ, Ancukiewicz M, Kobayashi W, Ryan DP, Blaszkowsky LS, et al. Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys. 2011;81(5):e735–41.CrossRef Margalit DN, Mamon HJ, Ancukiewicz M, Kobayashi W, Ryan DP, Blaszkowsky LS, et al. Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys. 2011;81(5):e735–41.CrossRef
30.
Zurück zum Zitat Cai X, Wu H, Peng J, Zhu J, Cai S, Cai G, et al. Tolerability and outcomes of radiotherapy or chemoradiotherapy for rectal cancer in elderly patients aged 70 years and older. Radiat Oncol. 2013;8:86.CrossRef Cai X, Wu H, Peng J, Zhu J, Cai S, Cai G, et al. Tolerability and outcomes of radiotherapy or chemoradiotherapy for rectal cancer in elderly patients aged 70 years and older. Radiat Oncol. 2013;8:86.CrossRef
31.
Zurück zum Zitat Guimas V, Boustani J, Schipman B, Lescut N, Puyraveau M, Bosset JF, et al. Preoperative chemoradiotherapy for rectal cancer in patients aged 75 years and older: acute toxicity, compliance with treatment, and early results. Drugs Aging. 2016;33(6):419–25.CrossRef Guimas V, Boustani J, Schipman B, Lescut N, Puyraveau M, Bosset JF, et al. Preoperative chemoradiotherapy for rectal cancer in patients aged 75 years and older: acute toxicity, compliance with treatment, and early results. Drugs Aging. 2016;33(6):419–25.CrossRef
32.
Zurück zum Zitat De Felice F, Llange K, Rubini F, Bulzonetti N, Caiazzo R, Musio D, et al. Intensified neoadjuvant chemoradiotherapy for locally advanced rectal cancer in elderly patients: toxicity, disease control, and survival outcomes. Clin Colorectal Cancer. 2018;17(1):e77–81.CrossRef De Felice F, Llange K, Rubini F, Bulzonetti N, Caiazzo R, Musio D, et al. Intensified neoadjuvant chemoradiotherapy for locally advanced rectal cancer in elderly patients: toxicity, disease control, and survival outcomes. Clin Colorectal Cancer. 2018;17(1):e77–81.CrossRef
33.
Zurück zum Zitat Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2018. 16(7):874–901. Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2018. 16(7):874–901.
34.
Zurück zum Zitat De Felice F, D’Ambrosio G, Musio D, Iafrate F, Benevento I, Marzo M, et al. Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II study. Oncotarget. 2018;9(72):33702–33,709.CrossRef De Felice F, D’Ambrosio G, Musio D, Iafrate F, Benevento I, Marzo M, et al. Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II study. Oncotarget. 2018;9(72):33702–33,709.CrossRef
35.
Zurück zum Zitat •• Montroni I, Ugolini G, Saur NM, Spinelli A, Rostoft S, Millan M, et al. Personalized management of elderly patients with rectal cancer: expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. Eur J Surg Oncol. 2018;44(11):1685–702 International clinical guidelines in elderly patients with rectal cancer.CrossRef •• Montroni I, Ugolini G, Saur NM, Spinelli A, Rostoft S, Millan M, et al. Personalized management of elderly patients with rectal cancer: expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. Eur J Surg Oncol. 2018;44(11):1685–702 International clinical guidelines in elderly patients with rectal cancer.CrossRef
36.
Zurück zum Zitat Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479–516.CrossRef Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479–516.CrossRef
37.
Zurück zum Zitat Wang SJ, Hathout L, Malhotra U, Maloney-Patel N, Kilic S, Poplin E, et al. Decision-making strategy for rectal cancer management using radiation therapy for elderly or comorbid patients. Int J Radiat Oncol Biol Phys. 2018;100(4):926–44.CrossRef Wang SJ, Hathout L, Malhotra U, Maloney-Patel N, Kilic S, Poplin E, et al. Decision-making strategy for rectal cancer management using radiation therapy for elderly or comorbid patients. Int J Radiat Oncol Biol Phys. 2018;100(4):926–44.CrossRef
38.
Zurück zum Zitat Hallam S, Messenger DE, Thomas MG. A systematic review of local excision after neoadjuvant therapy for rectal cancer: are ypT0 tumors the limit? Dis Colon Rectum. 2016;59(10):984–97.CrossRef Hallam S, Messenger DE, Thomas MG. A systematic review of local excision after neoadjuvant therapy for rectal cancer: are ypT0 tumors the limit? Dis Colon Rectum. 2016;59(10):984–97.CrossRef
39.
Zurück zum Zitat Appelt AL, Pløen J, Vogelius IR, Bentzen SM, Jakobsen A. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(1):74–80.CrossRef Appelt AL, Pløen J, Vogelius IR, Bentzen SM, Jakobsen A. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(1):74–80.CrossRef
40.
Zurück zum Zitat Gerard JP, Chapet O, Ramaioli A, Romestaing P. Long-term control of T2-T3 rectal adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2002;54(1):142–9.CrossRef Gerard JP, Chapet O, Ramaioli A, Romestaing P. Long-term control of T2-T3 rectal adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2002;54(1):142–9.CrossRef
41.
Zurück zum Zitat Corner C, Bryant L, Chapman C, Glynne-Jones R, Hoskin PJ. High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Brachytherapy. 2010;9(1):66–70.CrossRef Corner C, Bryant L, Chapman C, Glynne-Jones R, Hoskin PJ. High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Brachytherapy. 2010;9(1):66–70.CrossRef
42.
Zurück zum Zitat Habr-Gama A, Gama-Rodrigues J, São Julião GP, Proscurshim I, Sabbagh C, Lynn PB, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2014;88(4):822–8.CrossRef Habr-Gama A, Gama-Rodrigues J, São Julião GP, Proscurshim I, Sabbagh C, Lynn PB, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2014;88(4):822–8.CrossRef
Metadaten
Titel
Locally Advanced Rectal Cancer: Treatment Approach in Elderly Patients
verfasst von
Francesca De Felice, PhD
Daniele Crocetti, PhD
Veronica Maiuri, MD
Martina Parisi, MD
Francesco Marampon, PhD
Luciano Izzo, FP
Giorgio De Toma, FP
Daniela Musio, MD
Vincenzo Tombolini, FP
Publikationsdatum
01.01.2020
Verlag
Springer US
Erschienen in
Current Treatment Options in Oncology / Ausgabe 1/2020
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-019-0692-8

Weitere Artikel der Ausgabe 1/2020

Current Treatment Options in Oncology 1/2020 Zur Ausgabe

Palliative and Supportive Care (MP Davis, Section Editor)

Chemotherapy-Induced Sarcopenia

Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Opioids in Cancer Development, Progression and Metastasis: Focus on Colorectal Cancer

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.